Breaking News

EU Targets Bortnikov, Head of Russian Secret Service, in Draft of Sanctions
Tweet TWEET

Terumo Begins Commercial Distribution of BSD's MicroThermX® Microwave Ablation System at ECIO Following Successful Training of

  Terumo Begins Commercial Distribution of BSD's MicroThermX® Microwave
  Ablation System at ECIO Following Successful Training of Sales Personnel

Business Wire

SALT LAKE CITY -- July 8, 2013

BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) reports
completion of intensive training of Terumo sales personnel in preparation for
the commercial launch by Terumo Europe NV (Terumo) of BSD's MicroThermX^®
Microwave Ablation System (MicroThermX) at the European Conference on
Interventional Oncology (ECIO). BSD and Terumo conducted successful training
of 80 Terumo sales personnel prior to the commercial launch. The increasing
role of microwave ablation and MicroThermX were featured at ECIO. Terumo and
BSD co-sponsored an educational symposium and workshops highlighting the
MicroThermX, which were well attended and led to many potential customer
contacts. ECIO is a comprehensive international meeting focused exclusively on
the rapidly growing field of interventional oncology, a key market for BSD's
microwave ablation products. Leading interventional oncology experts from over
60 countries attended the conference.

“The ECIO meeting significantly increased the profile of the Company’s line of
microwave ablation products,” stated Sam Maravich, VP of Sales and Marketing
BSD. “The tremendous success of the MicroThermX exhibit was evident by a
constant stream of interested clinicians from around the world. The success of
the meeting reflects the dynamic growth of microwave ablation throughout the
world."

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia), while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market, and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

About Terumo Corporation

A world leader in state-of-the-art medical devices and interventional
oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2012 sales of
nearly $5 billion and has a market cap in excess of $8 billion. Through the
sale and promotion of a high quality line of devices used for tumor
embolization, the closing or blocking of blood vessels, Terumo Europe NV has
established itself as a pioneer in the field of interventional oncology.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the expected use of proceeds relating to the
recently completed offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
fax: 801-972-5930
investor@bsdmc.com